{"schemaVersion":1,"language":"en","canonical":"https://cbd.bike/guides/cbd-for-pain/","question":"CBD for pain: what was actually studied?","answer":"CBD pain findings depend on the condition and formulation, and some trials report no advantage over placebo. Evidence for cannabis or a THC–CBD medicine cannot establish that a retail CBD oil, gummy or cream relieves pain.","author":{"type":"Organization","name":"Cryptobedrock"},"sourceReviewDate":"2026-10-19","comparison":{"introduction":"Read the condition and the comparison before generalizing a pain result. These studies did not test an ordinary retail cream or gummy.","columns":["Population and design","Measured result","Transfer limit"],"rows":[["Fibromyalgia: 200 randomized; 24 weeks","The pain comparison favored placebo.","This finding concerns the tested oral CBD regimen and condition."],["Spinal-cord-injury neuropathic pain: 40 randomized, 38 analyzed; six-week crossover periods","CBD–placebo difference −0.54 on a 0–10 pain scale; 95% CI −0.88 to −0.21.","A modest mean difference in a specific study population."],["A different condition or retail formulation","No result is supplied by these two studies.","Check a matching trial rather than borrowing a condition’s outcome."]]},"interpretationScope":"These trials used different conditions and study protocols. Their research regimens are not consumer dosing advice.","nextStep":"For the next pain claim you read, write down condition, formulation, comparison and outcome unit before accepting its conclusion.","sources":[{"title":"NCCIH · Cannabis and cannabinoids","url":"https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know"},{"title":"FDA · CBD: risks, side effects and unknowns","url":"https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis"},{"title":"Rasmussen et al. · Fibromyalgia randomized trial","url":"https://pubmed.ncbi.nlm.nih.gov/40846590/"},{"title":"Spinal-cord-injury neuropathic-pain trial, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42256679/"}],"sourceData":{"title":"In this fibromyalgia trial, placebo improved more","caption":"The trial randomized 200 adults with fibromyalgia, 100 per group. At 24 weeks, mean pain-score change was −0.4 with CBD and −1.1 with placebo; the between-group result favored placebo. Lines show the published 95% confidence intervals for each mean change.","columns":["Randomized group","Mean change (0–10 scale)","95% confidence interval"],"rows":[["CBD, n = 100","−0.4","−0.82 to 0.08"],["Placebo, n = 100","−1.1","−1.53 to −0.63"]],"scope":"This was one single-centre trial of a defined CBD tablet formulation, studied at 50 mg daily. That is study context, not use guidance. It does not settle other pain conditions or validate retail oils, gummies or creams.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40846590/"}}